Literature DB >> 3561251

Secondary structure prediction of human SAA1. Presumptive identification of calcium and lipid binding sites.

W Turnell, R Sarra, I D Glover, J O Baum, D Caspi, M L Baltz, M B Pepys.   

Abstract

Serum amyloid A protein (SAA), an apolipoprotein of high density lipoprotein (HDL), is an acute phase protein thought to be the precursor of amyloid fibrils in reactive systemic (AA) amyloidosis. A prediction of the secondary structure of the human serum amyloid protein SAA1(alpha) is presented. The prediction was based upon one-dimensional Fourier analysis of the amino acid sequence together with sequence matching to known structural motifs. The results were compared with those from prediction algorithms based upon statistical techniques. Our findings are consistent with available experimental data. They include the putative identification of the amino-terminal 11 residues as the functionally important lipid-binding site of SAA and of a likely, neutral, calcium-binding sequence: Gly48-Pro49-Gly50-Gly51. Sequence comparisons between SAA and protein tyrosine kinases, phospholipases A2 and delta-crystallin, all of which bind both calcium and phospholipid, revealed significant homologies that support our proposals concerning structure-function relationships in SAA.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3561251

Source DB:  PubMed          Journal:  Mol Biol Med        ISSN: 0735-1313


  18 in total

1.  A cell culture system for the study of amyloid pathogenesis. Amyloid formation by peritoneal macrophages cultured with recombinant serum amyloid A.

Authors:  B Kluve-Beckerman; J J Liepnieks; L Wang; M D Benson
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

2.  Impact of individual acute phase serum amyloid A isoforms on HDL metabolism in mice.

Authors:  Myung-Hee Kim; Maria C de Beer; Joanne M Wroblewski; Richard J Charnigo; Ailing Ji; Nancy R Webb; Frederick C de Beer; Deneys R van der Westhuyzen
Journal:  J Lipid Res       Date:  2016-03-27       Impact factor: 5.922

3.  Urea-induced denaturation of apolipoprotein serum amyloid A reveals marginal stability of hexamer.

Authors:  Limin Wang; Wilfredo Colón
Journal:  Protein Sci       Date:  2005-06-03       Impact factor: 6.725

4.  The lipidation status of acute-phase protein serum amyloid A determines cholesterol mobilization via scavenger receptor class B, type I.

Authors:  Gunther Marsche; Sasa Frank; John G Raynes; Karen F Kozarsky; Wolfgang Sattler; Ernst Malle
Journal:  Biochem J       Date:  2007-02-15       Impact factor: 3.857

5.  ATP binding cassette G1-dependent cholesterol efflux during inflammation.

Authors:  Maria C de Beer; Ailing Ji; Anisa Jahangiri; Ashley M Vaughan; Frederick C de Beer; Deneys R van der Westhuyzen; Nancy R Webb
Journal:  J Lipid Res       Date:  2010-12-07       Impact factor: 5.922

6.  Molecular cloning and nucleotide sequence of the alpha-toxin (phospholipase C) of Clostridium perfringens.

Authors:  R W Titball; S E Hunter; K L Martin; B C Morris; A D Shuttleworth; T Rubidge; D W Anderson; D C Kelly
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

7.  Murine apolipoprotein serum amyloid A in solution forms a hexamer containing a central channel.

Authors:  Limin Wang; Hilal A Lashuel; Thomas Walz; Wilfredo Colon
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-27       Impact factor: 11.205

8.  pH-dependent structural transitions of Alzheimer amyloid peptides.

Authors:  P E Fraser; J T Nguyen; W K Surewicz; D A Kirschner
Journal:  Biophys J       Date:  1991-11       Impact factor: 4.033

9.  Expression of recombinant human serum amyloid A in mammalian cells and demonstration of the region necessary for high-density lipoprotein binding and amyloid fibril formation by site-directed mutagenesis.

Authors:  H Patel; J Bramall; H Waters; M C De Beer; P Woo
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

10.  Fibronectin and basement membrane components in renal amyloid deposits in patients with primary and secondary amyloidosis.

Authors:  G T Westermark; B Norling; P Westermark
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.